secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001770787-23-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q2 revenue $146.8M (+28% YoY); raises FY2023 guidance to $600-620M
-------------------------------------------------------------------------------

- Revenue $146.8M in Q2, +28% YoY from $114.6M.
- Gross margin 68% vs 76% prior year, down on product mix from new launches.
- Net loss $62.4M vs $64.5M YoY; stock-based compensation expense $45.7M.
- Raises FY2023 revenue guidance to $600-620M from prior $590-610M, 16-20% growth.
- Accelerated Xenium in situ platform momentum; launched Visium CytAssist Gene & Protein Expression assay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/0001770787-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/txg-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001770787-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer